Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor …
D Poon, MH Tan, D Khor - BMJ Case Reports CP, 2021 - casereports.bmj.com
D Poon, MH Tan, D Khor
BMJ Case Reports CP, 2021•casereports.bmj.comWe report a case of a frail 68-year-old woman with stage 4 pancreatic carcinoma harbouring
a fibroblastic growth factor receptor 2 (FGFR2) fusion who achieved a durable complete
response after treatment with erdafitinib a pan-FGFR inhibitor. The FGFR2-TACC2 fusion
was detected on comprehensive tumour somatic mutation profiling. There is ongoing
complete response at 10 months after initiation of erdafitinib. Transient central serous
retinopathy, grade 2 hyperphosphataemia and diarrhoea were the adverse events …
a fibroblastic growth factor receptor 2 (FGFR2) fusion who achieved a durable complete
response after treatment with erdafitinib a pan-FGFR inhibitor. The FGFR2-TACC2 fusion
was detected on comprehensive tumour somatic mutation profiling. There is ongoing
complete response at 10 months after initiation of erdafitinib. Transient central serous
retinopathy, grade 2 hyperphosphataemia and diarrhoea were the adverse events …
We report a case of a frail 68-year-old woman with stage 4 pancreatic carcinoma harbouring a fibroblastic growth factor receptor 2 (FGFR2) fusion who achieved a durable complete response after treatment with erdafitinib a pan-FGFR inhibitor. The FGFR2-TACC2 fusion was detected on comprehensive tumour somatic mutation profiling. There is ongoing complete response at 10 months after initiation of erdafitinib. Transient central serous retinopathy, grade 2 hyperphosphataemia and diarrhoea were the adverse events encountered.
casereports.bmj.com